Vitality Biopharma Developing Cannabis-derived Prodrugs for Inflammatory Bowel Disease

Click here to receive IBD news via e-mail

VitalitylogoVitality Biopharma of California has developed a new class of cannabis-derived cannabinoid prodrugs, known as cannabosides, which can enable the selective delivery of cannabidiol (CBD), a cannabinoid compound, to the intestinal tract, and reduce the delivery of the psychoactive tetrahydrocannabinol (THC) to the brain.

Vitality Biopharma, which is developing cannabinoid prodrug pharmaceuticals to treat neurological and inflammatory disorders, has released an update on its clinical development roadmap, which includes cannabosides for the treatment of inflammatory bowel disease (IBD). The company, formerly known as Stevia First Corp, changed its name to Vitality Biopharma, Inc., in June with the goal of developing these pharmaceuticals.

Vitality explains that prodrugs are medications or compounds that are metabolized (i.e., converted within the body) into a pharmacologically active drug, often to

... read more at: